|
||||||||||||||||
|
||||||||||||||||
The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. HIPAA Health Insurance Portability and Accountability Act IOM Institute of Medicine IP Intellectual property IRB Institutional Review Board IVDMIA In Vitro Diagnostic Multivariate Index Assay MIAME Minimum Information About a Microarray Experiment MMRC Multiple Myeloma Research Consortium NBN National Biospecimen Network NCI National Cancer Institute NICE U.K. National Institute for Clinical Excellence NIH National Institutes of Health NIST National Institute of Standards and Technology NLA National limitation amount OBQI Oncology Biomarker Qualification Initiative PBRC Pharmaceutical Biomedical Research Consortium PET Positron emission tomography PMA Premarket approval PPP Public–private partnerships PSA Prostate-specific antigen PSI Protein Structure Initiative SACGT Secretary’s Advisory Committee on Genetic Testing SEMATECH Semiconductor Manufacturing Technology SNP Single nucleotide polymorphism TRWG Translational Research Working Group TSC The SNP Consortium USPSTF U.S. Preventive Services Task Force GLOSSARYAllele—any one of a series of two or more different genes that occupy the same position (locus) on a chromosome. Amplification—a process by which specific genetic material is increased. For some cancers, the number of copies of specific genes is higher than normal. These genes are said to be amplified. Analyte-specific reagent (ASR)—antibodies, both polyclonal and monoclonal, specific receptor proteins, ligands, nucleic acid sequences, and similar reagents, which through specific binding or chemical reaction with substances in a specimen are intended to be used in a diagnos-
|
|
|||||||||||||||
